Adaptimmune granted Nasdaq extension to Dec 1, 2025 to regain $1 bid compliance

Adaptimmune Therapeutics PLC

Nasdaq Hearings Panel granted exception until December 1, 2025 to meet minimum $1.00 bid price per share.
Notice received on September 22, 2025; failure to comply by deadline will lead to delisting of ADSs.
If non-compliant by December 1, 2025, trading will be suspended and delisting proceedings will commence.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.